Pectoral Nerve Block II and Erector Spine Plane Block in Breast Cancer Surgery
NCT ID: NCT04135157
Last Updated: 2021-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2019-07-01
2020-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Bi-level Erector Spine Plane Block and Combined Pectoral I-II Block in Breast Surgery
NCT04689581
Analgesic Efficacy of Erector Spinae Plane Block After Breast Cancer Surgery
NCT04512391
Rhomboid Intercostal Block vs Erector Spina Plan Block for Peri-operative Analgesia in Mastectomy
NCT04259502
Erector Spina Plane Block vs Serratus Anterior Plane Block for Postoperative Mastectomy Pain
NCT04296188
The Effect of Double Injection Erector Spinae Plane Block on Postoperative Pain Following Breast Surgery
NCT03415646
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is to survey that ESP and PECS II may supply acute and chronic analgesia by reducing pain scores in the first 24 hours and 3 months after the surgery, also the comparison of the analgesic activity among themselves for acute / chronic pain and opioid consumption will be searched.
In this study patients are divided into three groups. Patients in PECS group will have PECS II block in a separate section from the operating rooms (PNB practice room). In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively.
Patients in ESP group will have ESP block in a separate section from the operating rooms (PNB practice room). In addition, PCA will be used in the first 24 hours postoperatively.
Patients in control group will not be performed nerve block. Only general anesthesia (GA) will be performed in the operation room. In addition, PCA will be used in the first 24 hours postoperatively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PECS II or ESP
PECS II or ESP block are performed 30 minutes before general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
Pectoralis nerve block II
PECS II block will be performed 30 min. before general anesthesia.
Erector spine plane block
ESP block will be performed 30 minutes before general anesthesia.
Control
In the control group, patients will have only general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
Control
Only general anesthesia will be performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pectoralis nerve block II
PECS II block will be performed 30 min. before general anesthesia.
Erector spine plane block
ESP block will be performed 30 minutes before general anesthesia.
Control
Only general anesthesia will be performed.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Obesity (\> 100 kg, BMI\> 35 kg / m2)
* Patients undergoing bilateral mastectomy
* Pregnancy
* Contraindication of regional anesthesia (coagulopathy, abnormal INR, thrombocytopenia, infection at the injection site)
* Serious renal, cardiac, hepatic disease
* Hypersensitivity to local anesthetics or a history of allergy
* Patients with a history of opioid use longer than four weeks
* Patients with psychiatric disorders or communication difficulties
* Patients with chest deformity
* Patients with previous breast surgery except diagnostic biopsies
* Patients who do not want to participate
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CENGİZ KAYA (ckaya)
UNKNOWN
Ondokuz Mayıs University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Caner Genç
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
CENGİZ KAYA, MD
Role: STUDY_DIRECTOR
Ondokuz Mayıs University Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ondokuz Mayıs University Faculty of Medicine
Samsun, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA191001001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.